Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Quarterly Stats and Totals ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Snowballgrowthon Nov 14, 2021 9:33am
151 Views
Post# 34124467

RE:RE:RE:RE:Quarterly Stats and Totals ...

RE:RE:RE:RE:Quarterly Stats and Totals ...
MrMugsy wrote:
EbbFlow88 wrote: Also, after listening to the conference call I believe that Samira will be a fantastic CEO. She's extremely sharp and I think she's building a hell of a team. She seems tough but driven and it seems her team is laser focused.


Yes - Samira is strong on the financial side and she has proven herself once before.
She is adding strength around her in those areas where it's needed.
Many on the team are from Paladin and they know how to grow a drug company in this manner.
Others are experienced and fill needed voids.
They even have early ROW experience in South Africa and many small acquisitions over 19 previous years.

Goodman and the Board will guide strategy - and that should move faster now.

Also, the ROW structure will amplify sales potential.

It will be exciting !!!!!





They said in the conference call that the pipeline of deals is full... maybe they have some saleforce underused

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities